Should I buy or sell Palatin Technologies stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks .

What is Palatin Technologies' stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Palatin Technologies' stock. Their PTN share price targets range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 3,053.2% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts .

How have PTN shares performed in 2023?

Palatin Technologies' stock was trading at $3.87 at the start of the year. Since then, PTN shares have decreased by 42.6% and is now trading at $2.22. View the best growth stocks for 2023 here .

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 748,300 shares, an increase of 40.1% from the October 15th total of 534,300 shares. Based on an average daily volume of 116,900 shares, the days-to-cover ratio is presently 6.4 days. Currently, 5.5% of the company's shares are sold short. View Palatin Technologies' Short Interest .

When is Palatin Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our PTN earnings forecast .

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.07. The biopharmaceutical company had revenue of $2.11 million for the quarter, compared to analysts' expectations of $1.87 million. Palatin Technologies had a negative trailing twelve-month return on equity of 583.06% and a negative net margin of 413.38%. During the same quarter last year, the company posted ($0.86) EPS.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , Alliqua Biomedical (ALQA) , Catalyst Pharmaceuticals (CPRX) , AVEO Pharmaceuticals (AVEO) , ImmunoGen (IMGN) , TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM) .

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.24%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Palatin Technologies Stock Price, News & Analysis (NYSEAMERICAN:PTN)

$2.22

+0.22 (+11.00%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.95
▼
$2.22
50-Day Range: $1.97
▼
$2.91
52-Week Range: $1.43
▼
$5.00

Volume: 134,517 shs
Average Volume: 62,675 shs
Market Capitalization: $30.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $70.00

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Ownership SEC Filings Short Interest

Palatin Technologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,053.2% Upside
$70.00 Price Target
Short Interest: Healthy
4.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $70.00, Palatin Technologies has a forecasted upside of 3,053.2% from its current price of $2.22.
Amount of Analyst Coverage
Palatin Technologies has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.87% of the float of Palatin Technologies has been sold short.
Short Interest Ratio / Days to Cover
Palatin Technologies has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Palatin Technologies has recently decreased by 10.77%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Palatin Technologies does not currently pay a dividend.
Dividend Growth
Palatin Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTN.

0.6

News and Social Media Coverage

Search Interest
Only 8 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
12 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Palatin Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Palatin Technologies is held by insiders.
Percentage Held by Institutions
Only 7.86% of the stock of Palatin Technologies is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Palatin Technologies is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Palatin Technologies is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Palatin Technologies Stock (NYSEAMERICAN:PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

PTN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTN Stock News Headlines

November 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Palatin Technologies (PTN) and ProKidney (PROK)

November 15, 2023 | finance.yahoo.com

Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 15, 2023 | markets.businessinsider.com

Palatin Technologies Receives Buy Rating: F1Q24 Results Surpass Expectations and MELODY-1 Trial Shows Promising Progress

November 15, 2023 | finance.yahoo.com

Q1 2024 Palatin Technologies Inc Earnings Call

November 14, 2023 | markets.businessinsider.com

Palatin Technologies Inc. Q1 Loss decreases, but misses estimates

November 14, 2023 | finance.yahoo.com

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

November 13, 2023 | finance.yahoo.com

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 9, 2023 | finance.yahoo.com

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

October 25, 2023 | msn.com

ImmunityBio, Palatin Technologies among healthcare movers

October 25, 2023 | investing.com

Earnings call: Palatin reports strong growth and optimistic future plans in Q4 2023 earnings call

October 24, 2023 | finance.yahoo.com

Palatin Announces Closing of $5 Million Registered Direct Offering

October 23, 2023 | marketwatch.com

Palatin Technologies Shares Drop 13% After Private Placement Prices

October 23, 2023 | finance.yahoo.com

Palatin Announces $5 Million Registered Direct Offering

October 19, 2023 | finanznachrichten.de

Financialnewsmedia.com: Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

October 18, 2023 | markets.businessinsider.com

Palatin: GLP-1 & MC4R Agonist Co-administration Data Shows Increased Weight Loss

October 18, 2023 | finance.yahoo.com

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

October 16, 2023 | finance.yahoo.com

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

October 13, 2023 | finance.yahoo.com

Palatin Receives Notice of Non-Compliance from NYSE American

October 3, 2023 | finance.yahoo.com

Palatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call Transcript

September 30, 2023 | markets.businessinsider.com

Palatin Technologies Earns Buy Rating Amid Strong Performance and Promising Clinical Developments

September 29, 2023 | msn.com

Palatin Technologies: Falls as quarterly profit misses estimate

September 29, 2023 | markets.businessinsider.com

Buy Rating for Palatin Technologies: Promising Clinical Programs and High Upside Potential

September 29, 2023 | finance.yahoo.com

Q4 2023 Palatin Technologies Inc Earnings Call

September 28, 2023 | marketwatch.com

Palatin Technologies Shares Fall 10% After Wider-Than-Expected 4Q Loss

September 28, 2023 | finance.yahoo.com

Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/02/2023
Next Earnings (Estimated): 2/13/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:PTN
Previous Symbol: NYSE:PTN
CUSIP: N/A
CIK: 911216
Web: www.palatin.com
Phone: (609) 495-2200
Fax: 609-495-2202
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $70.00
High Stock Price Target: $70.00
Low Stock Price Target: $70.00
Potential Upside/Downside: +3,053.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,540,000.00
Net Margins: -413.38%
Pretax Margin: -490.15%
Return on Equity: -583.06%
Return on Assets: -142.33%

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 0.72
Quick Ratio: 0.60

Sales & Book Value

Annual Sales: $4.85 million
Price / Sales: 6.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.36) per share
Price / Book: -6.17

Miscellaneous

Outstanding Shares: 13,740,000
Free Float: 12,679,000
Market Cap: $30.50 million
Optionable: Not Optionable
Beta: 0.91

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Carl Spana Ph.D. (Age 61)
Co-Founder, President, CEO & Director
Comp: $979k
Mr. Stephen T. Wills CPA (Age 66)
MST, CFO, COO, Executive VP, Treasurer & Secretary
Comp: $910.55k
Burns McClellan
Vice President of Investor Relations
Mr. Stephen A. Slusher Esq.
Chief Legal Officer
Dr. Michael B. Raizman M.D.
Chief Medical Officer
Mr. James E. Hattersley (Age 63)
Senior Vice President of Business Development
Mr. John Dodd Ph.D.
Senior Vice President of Preclinical Development
Mr. Robert Jordan
Senior Vice President of Program Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

PTN Stock Analysis - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings or view top-rated stocks.
What is Palatin Technologies' stock price target for 2024?: 1 equities research analysts have issued twelve-month target prices for Palatin Technologies' stock. Their PTN share price targets range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 3,053.2% from the stock's current price.
View analysts price targets for PTN or view top-rated stocks among Wall Street analysts.
How have PTN shares performed in 2023?: Palatin Technologies' stock was trading at $3.87 at the start of the year. Since then, PTN shares have decreased by 42.6% and is now trading at $2.22.
View the best growth stocks for 2023 here.
Are investors shorting Palatin Technologies?: Palatin Technologies saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 748,300 shares, an increase of 40.1% from the October 15th total of 534,300 shares. Based on an average daily volume of 116,900 shares, the days-to-cover ratio is presently 6.4 days. Currently, 5.5% of the company's shares are sold short.
View Palatin Technologies' Short Interest.
When is Palatin Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our PTN earnings forecast.
How were Palatin Technologies' earnings last quarter?: Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.07. The biopharmaceutical company had revenue of $2.11 million for the quarter, compared to analysts' expectations of $1.87 million. Palatin Technologies had a negative trailing twelve-month return on equity of 583.06% and a negative net margin of 413.38%. During the same quarter last year, the company posted ($0.86) EPS.

When did Palatin Technologies' stock split?: Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Palatin Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).
Who are Palatin Technologies' major shareholders?: Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.24%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Palatin Technologies?: Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PTN) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial